537,338 Shares in Silence Therapeutics plc (NASDAQ:SLN) Purchased by First Turn Management LLC

First Turn Management LLC purchased a new position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 537,338 shares of the company's stock, valued at approximately $10,209,000. First Turn Management LLC owned approximately 1.80% of Silence Therapeutics as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Parkman Healthcare Partners LLC lifted its stake in shares of Silence Therapeutics by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company's stock valued at $4,046,000 after buying an additional 40,063 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company's stock valued at $151,000 after acquiring an additional 667 shares in the last quarter. Redmile Group LLC bought a new position in shares of Silence Therapeutics in the first quarter worth about $43,798,000. Janus Henderson Group PLC purchased a new stake in shares of Silence Therapeutics during the first quarter worth about $13,575,000. Finally, Lynx1 Capital Management LP raised its stake in Silence Therapeutics by 123.4% during the 1st quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company's stock valued at $11,375,000 after purchasing an additional 290,855 shares during the period. Institutional investors own 98.73% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SLN shares. HC Wainwright restated a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, August 30th. Jefferies Financial Group began coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They set a "buy" rating and a $40.00 target price for the company. Morgan Stanley lifted their price target on shares of Silence Therapeutics from $45.00 to $49.00 and gave the company an "overweight" rating in a report on Friday, June 28th. Finally, Chardan Capital reiterated a "buy" rating and issued a $55.00 price target on shares of Silence Therapeutics in a research note on Friday, August 16th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Silence Therapeutics presently has a consensus rating of "Buy" and an average price target of $57.20.

Silence Therapeutics Stock Up 0.6 %

Silence Therapeutics stock traded up $0.11 during mid-day trading on Friday, reaching $18.69. 86,495 shares of the company's stock traded hands, compared to its average volume of 208,354. Silence Therapeutics plc has a 12-month low of $6.15 and a 12-month high of $27.72. The stock has a 50 day moving average of $18.75 and a two-hundred day moving average of $20.73. The company has a market cap of $559.39 million, a price-to-earnings ratio of -16.11 and a beta of 1.29.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.10). Silence Therapeutics had a negative net margin of 222.44% and a negative return on equity of 58.28%. The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $11.28 million. As a group, sell-side analysts forecast that Silence Therapeutics plc will post -1.55 earnings per share for the current year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.